anaphylaxis
Immunology · 2016–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adrenaline (epinephrine) Emergency treatment of acute severe allergic reactions in children or adults at significant risk of anaphylaxis. | Mar 2026 | Recommended with restriction | input received National Allergy Council · Australasian Society of Clinical Immunology and Allergy · Anaphylaxis Australia · Pharmaceutical Society of Australia · National Aboriginal Community Controlled Health Organisation · Healthcare Australasia |
| adrenaline (epinephrine) Emergency treatment of acute allergic reaction with anaphylaxis. Treatment of patients with a significant risk of anaphylaxis. | Jul 2024 | Recommended with restriction | input received Anaphylaxis Australia · Australasian Society of Clinical Immunology and Allergy · National Allergy Council |
| adrenaline (epinephrine) Treatment of acute allergic reaction with anaphylaxis in patients assessed to be at significant risk of anaphylaxis, or discharged from hospital/emergency… | Nov 2020 | Recommended with restriction | input received |
| adrenaline Acute allergic reaction with anaphylaxis in patients at significant risk, for emergency treatment. | Mar 2018 | Recommended with restriction | no section in document |
| adrenaline Self-administered intramuscular injection for emergency treatment of anaphylaxis in adults and juveniles. | Mar 2018 | Deferred | unclear |
| adrenaline Acute allergic reaction with anaphylaxis. For use in severe allergic reactions due to insect stings or bites, foods, drugs or other allergens. | Jul 2016 | Recommended | input received |
| adrenaline Emergency treatment for anaphylactic reactions. The submission sought to list auto-injector forms of adrenaline in the Prescriber Bag section of the PBS as an… | Mar 2016 | Not recommended | none received |
Who spoke
Anaphylaxis Australia · Australasian Society of Clinical Immunology and Allergy · National Allergy Council · Pharmaceutical Society of Australia · National Aboriginal Community Controlled Health Organisation · Healthcare Australasia
What the PBS pays
$24M in government benefit over 2024–25, across 211,007 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adrenaline (epinephrine) | $23.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.